Präventive Kardiologie

Mahir Karakas; Wolfgang Koenig

doi:10.1055/s-0032-1325996

Kardiologie up2date, Inhaltsverzeichnis

Kardiologie up2date 2012; 08(04): 321-334
DOI: 10.1055/s-0032-1325996

Koronare Herzerkrankung und Atherosklerose

Präventive Kardiologie

Mahir Karakas

,

Wolfgang Koenig

Abstract

Alle Artikel dieser Rubrik

Abstract

Cardiovascular disease (CVD) remains the major cause of premature death in Europe, even though CVD mortality has fallen considerably over recent decades. Importantly, it is strongly connected to lifestyle habits, one reason why preventive strategies are effective. While 50 % of the reductions seen in coronary heart disease (CHD) mortality relate to changes in risk factors, 40 % relate to improved treatments. The aim of this manuscript, which focuses on several important topics contained in the 2012 guidelines from the Fifth Joint Task Force of the European Societies on Cardiovascular Disease Prevention in Clinical Practice, is to give an update of the present knowledge in preventive cardiology for physicians and other health care workers.

Volltext

Referenzen

Literatur
1 A Dictionary of Epidemiology. 4th ed. New York: Oxford University Press; 2001
2 Perk J, De Backer G, Gohlke H et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J 2012; 33: 1635-1701
3 Prescott E, Hippe M, Schohr P et al. Smoking and risk of myocardial infarction in women and men: longitudinal population study. BMJ 1998; 316: 1043-1047
4 Steenland K. Risk assessment for heart disease and workplace ETS exposure among nonsmokers. Environ Health Perspect 1999; 107 : 859-863
5 Fröhlich M, Sund M, Löwel H et al. Independent association of various smoking characteristics with markers of systemic inflammation in men. Results from a representative sample of the general population (MONICA Augsburg Survey 1994/95). Eur Heart J 2003; 24: 1365-1372
6 Nagel G, Arnold FJ, Wilhelm M et al. Environmental tobacco smoke and cardiometabolic risk in young children: results from a survey in south-west Germany. Eur Heart J 2009; 30: 1885-1893
7 Hurt RD, Weston SA, Ebbert JO et al. Myocardial Infarction and Sudden Cardiac Death in Olmsted County, Minnesota, Before and After Smoke-Free Workplace Laws. Arch Intern Med 2012; DOI
8 Mente A, de Koning L, Shannon HS et al. A systematic review of the evidence supporting a causal link between dietary factors and coronary heart disease. Arch Intern Med 2009; 169: 659-669
9 de Lorgeril M, Salen P, Martin Jl et al. Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: final report of the Lyon Diet Heart Study. Circulation 1999; 99: 779-785
10 Panagiotakos DB, Dimalopoulou K, Katsouyanni K et al. Mediterranean diet and inflammatory response in myocardial infarction survivors. Int J Epidemiol 2009; 38: 856-866
11 Sesso HD, Christen WG, Bubes V et al. Multivitamins in the prevention of cardiovascular disease in men: the Physicians' Health Study II randomized controlled trial. JAMA 2012; 308: 1751-1760
12 Autenrieth C, Schneider A, Döring A et al. Association between different domains of physical activity and markers of inflammation. Med Sci Sports Exerc 2009; 41: 1706-1713
13 Wing RR. Look AHEAD Research Group. Long-term effects of a lifestyle intervention on weight and cardiovascular risk factors in individuals with type 2 diabetes mellitus: four-year results of the Look AHEAD trial. Arch Intern Med 2010; 170: 1566-1575
14 Davidson KW, Rieckmann N, Clemow L et al. Enhanced depression care for patients with acute coronary syndrome and persistent depressive symptoms: coronary psychosocial evaluation studies randomized controlled trial. Arch Intern Med 2010; 170: 600-608
15 Rothenbacher D, Hahmann H, Wüsten B et al. Symptoms of anxiety and depression in patients with stable coronary heart disease: prognostic value and consideration of pathogenetic links. Eur J Cardiovasc Prev Rehabil 2007; 14: 547-554
16 Ladwig KH, Marten-Mittag B, Löwel H et al. Influence of depressive mood on the association of CRP and obesity in 3205 middle aged healthy men. Brain Behav Immun 2003; 17: 268-275
17 Lewinton S, Clarke R, Qizilbah N et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360: 1903-1913
18 Assmann G, Cullen P, Schulte H. Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular Münster (PROCAM) study. Circulation 2002; 105: 310-315
19 Marx N, Blessing E. Diabetes mellitus and coronary artery disease. Update on diagnosis and drug therapy. Dtsch Med Wochenschr 2007; 132: 1034-1038
20 Haffner SM, Lehto S, Rönnemaa T et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339: 229-234
21 Marx N, Froehlich J, Siam L et al. Antidiabetic PPAR gamma-activator rosiglitazone reduces MMP-9 serum levels in type 2 diabetic patients with coronary artery disease. Arterioscler Thromb Vasc Biol 2003; 23: 283-288
22 Beck JA, Meisinger C, Heier M et al. Effect of blood glucose concentrations on admission in non-diabetic versus diabetic patients with first acute myocardial infarction on short- and long-term mortality (from the MONICA/KORA Augsburg Myocardial Infarction Registry). Am J Cardiol 2009; 104: 1607-1612
23 Emerging Risk Factors Collaboration. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med 2011; 364: 829-841
24 Karakas M, Koenig W. Statine in der Primärprävention der koronaren Herzkrankheit. Kardio up 2010; 6: 283-287
25 Shepherd J, Cobbe SM, Ford I et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333: 1301-1307
26 Downs JR, Clearfield M, Weis S et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998; 279: 1615-1622
27 Nakamura H, Arakawa K, Itakura H et al. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial. Lancet 2006; 368: 1155-1163
28 Ridker PM, Danielson E, Fonseca FA et al. Rosuvastatin to prevent events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359: 2195-2207
29 Genest J, McPherson R, Frohlich J et al. 2009 Canadian cardiovascular society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult – 2009 recommendation. Can J Cardiol 2009; 25: 567-579